Quantcast
Last updated on April 23, 2014 at 1:22 EDT

Latest Genentech Stories

Asthma Drug Found Effective In Treatment Of Chronic Hives, Itchiness
2013-02-25 08:57:48

Lawrence LeBlond for redOrbit.com - Your Universe Online Though not the most common occurrence, researchers do sometimes discover drugs marketed for one particular disease, disorder or illness can work well in treating a totally different condition. One recent discovery was that of a popular diabetes drug that showed promise in treating ovarian cancer. Another--not so recent--discovery was of the antidepressant drug Wellbutrin that proved to be effective in helping smokers kick the habit....

2013-02-24 12:20:31

- Phase III study published in NEJM today and to be presented tomorrow met primary endpoint in moderate-to-severe chronic idiopathic urticaria (CIU) EAST HANOVER, N.J., Feb. 24, 2013 /PRNewswire/ -- Late-breaking results from ASTERIA II, a Phase III placebo-controlled study, showed positive results in patients with moderate to severe chronic idiopathic urticaria (CIU), referred to as chronic spontaneous urticaria (CSU) outside the United States, who remained symptomatic despite...

2013-02-18 08:23:10

BASEL, Switzerland, NEW YORK and JERUSALEM, Feb. 18, 2013 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) and Chiasma (pronounced key-az-ma) Inc., a privately held biopharma company, announced today that they have entered into an agreement to develop and commercialize Chiasma's proprietary product Octreolin, initially for acromegaly and subsequently for neuroendocrine tumors. Octreolin is an investigational oral form of the peptide octreotide, a somatostatin analog that is...

2013-02-12 08:29:59

LA JOLLA, Calif., Feb. 12, 2013 /PRNewswire/ -- RQx Pharmaceuticals, Inc. today announced that it has entered into a drug discovery collaboration with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), for the discovery and development of novel drug compounds for an undisclosed target. Under the terms of the agreement, RQx will receive an up-front payment and is eligible to receive research and development milestone payments totaling $111 million. In addition,...

2013-01-29 08:30:17

SAN DIEGO, Jan. 29, 2013 /PRNewswire/ -- Afraxis, Inc. today announced that it has entered into a global licensing agreement with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), to develop compounds for an undisclosed novel target. Under the terms of the agreement, Genentech will have exclusive, worldwide rights to develop and commercialize Afraxis' proprietary compounds. Afraxis is eligible to receive upfront, research, development and commercialization milestone...

2013-01-23 08:29:17

SEATTLE, Jan. 23, 2013 /PRNewswire/ -- Invictus Foundation(TM), a national nonprofit organization offering one on one and family behavioral health counseling services with licensed behavioral health providers to active duty military, National Guard, Reserve forces, veterans of Iraq, Afghanistan and their families regardless of their ability to pay announces a grant from Genentech to scale its Welcome Home Network program and services. "Through Genentech's generosity we will continue to raise...

2013-01-07 08:29:51

EXTON, Penn., Jan. 7, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, after one year on the market, 86 percent of U.S. retinal specialists have prescribed Regeneron's Eylea to at least one of their patients, a non-significant increase from six months post-launch (76 percent). Although Eylea prescriber base growth has been minimal, the mean Eylea patient volume per prescriber has...

2012-12-27 08:25:07

NEW YORK, Dec. 27, 2012 /PRNewswire/ -- Ohr Pharmaceutical Inc., a pharmaceutical company dedicated to the clinical development of new drugs for underserved therapeutic needs in large and growing markets, announced today that it has published a letter to shareholders, available on the Company's website, from its Chief Executive officer, Dr. Irach B. Taraporewala, Ph.D. The letter states: Dear Shareholder, I would like to take this opportunity to share the progress we have made in 2012 and...

2012-12-10 08:25:23

MISSISSAUGA, ON, Dec. 10, 2012 /CNW/ - Roche today announced updated survival results from the Phase III CLEOPATRA study, which showed that the combination of Perjeta® (pertuzumab), Herceptin® (trastuzumab) and docetaxel chemotherapy significantly extended the lives (overall survival) of people with previously untreated HER2-positive metastatic breast cancer (mBC), compared to Herceptin, chemotherapy and placebo. Results showed that the risk of death was reduced by 34...

2012-12-06 16:23:54

INCLINE VILLAGE, Nev., Dec. 6, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced royalty revenue guidance for the fourth quarter ending December 31, 2012, of approximately $86 million, as compared with actual royalty revenue of $73 million for the fourth quarter of 2011, an 18 percent increase. Total anticipated revenue for the year ended December 31, 2012, is $374 million as compared with actual results of $362 million for the year ended December 31, 2011, a...